Alnylam Pharmaceuticals Stock: Key Analyst Ratings Explored
Tuesday, 12 November 2024, 03:00
Alnylam Pharmaceuticals Stock Analysis
In the past three months, 24 analysts have provided insights regarding Alnylam Pharmaceuticals (NASDAQ:ALNY). These evaluations highlight the complexities of the financial landscape facing the company.
Key Findings from Analysts
- 26% of analysts recommend a buy rating for ALNY.
- 33% maintain a hold position.
- 41% suggest a sell rating, reflecting concerns about increasing financial risk.
Investor Awareness: Analyst ratings act as vital indicators for potential investors, offering a glimpse into market sentiment and future expectations for Alnylam Pharmaceuticals.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.